Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

CVS Health Corp., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income 2,047 2,265 1,914 2,142 2,300 (3,409) 2,961 2,313 1,296 1,587 2,791 2,224 975 1,219 2,986 2,012 1,744 1,529 1,931 1,427
Depreciation and amortization 1,134 1,127 1,104 1,001 1,049 1,056 1,087 1,055 1,115 1,134 1,137 1,126 1,139 1,114 1,102 1,086 1,096 1,092 1,072 1,111
Loss on assets held for sale 349 12 2,521
Store impairments 1,358
Goodwill impairment 431
Stock-based compensation 127 154 204 103 106 105 147 89 138 114 145 87 112 109 83 96 98 129 112 114
(Gain) loss on sale of subsidiary (250) (225) 2 (271) 205
Loss on early extinguishment of debt 89 363 674 766 79
Deferred income taxes and other noncash items 100 (447) (68) 155 507 (1,969) (94) (187) (173) (275) (204) (166) (473) 76 (66) (35) (352) 4 (195) 153
Accounts receivable, net (2,340) (3,116) (53) (751) (962) 678 (720) (1,967) 801 (1,120) (291) (2,093) 2,054 (1,331) 482 (2,715) 154 (1,631) 1,308 (1,989)
Inventories (72) (495) 972 828 (1,020) (884) 869 (400) (362) (420) 638 879 (1,018) (958) 462 541 (1,488) (526) (62) 1,001
Other assets 8 395 342 (1,255) (255) 14 27 (352) 29 113 78 (223) 575 349 559 (1,119) (240) (60) 75 (389)
Accounts payable and pharmacy claims and discounts payable 1,152 2,584 1,085 (1,203) 910 1,317 59 1,974 (1,075) 2,271 1,126 576 (726) 1,824 (257) 1,928 1,220 1,413 939 (22)
Health care costs payable and other insurance liabilities (4,285) 345 (48) 4,382 (3,440) 3,220 (11) 1,478 (179) 244 (190) 294 243 (59) (554) 139 (215) 39 (57) 553
Other liabilities (507) (445) 456 2,036 (909) 6,474 1,343 (440) 968 1,079 617 188 10 (964) 2,322 1,372 617 655 215 (11)
Change in operating assets and liabilities, net of effects from acquisitions (6,044) (732) 2,754 4,037 (5,676) 10,819 1,567 293 182 2,167 1,978 (379) 1,138 (1,139) 3,014 146 48 (110) 2,418 (857)
Adjustments required to reconcile net income to net cash provided by operating activities (4,683) 451 3,994 5,296 (4,252) 12,532 2,482 1,250 2,709 3,934 3,056 668 2,592 655 4,133 1,293 890 1,399 3,407 521
Net cash provided by operating activities (2,636) 2,716 5,908 7,438 (1,952) 9,123 5,443 3,563 4,005 5,521 5,847 2,892 3,567 1,874 7,119 3,305 2,634 2,928 5,338 1,948
Proceeds from sales and maturities of investments 2,182 1,907 1,749 1,891 1,194 1,175 1,790 2,570 1,687 1,612 1,770 2,177 2,677 1,080 1,422 1,288 1,433 1,830 1,800 1,986
Purchases of investments (2,418) (2,126) (2,141) (2,358) (1,307) (1,429) (1,536) (3,474) (2,546) (1,847) (2,439) (3,131) (3,262) (2,689) (2,153) (1,535) (1,523) (1,949) (2,015) (2,047)
Purchases of property and equipment (911) (545) (591) (984) (688) (580) (408) (1,051) (597) (608) (486) (829) (713) (534) (448) (742) (567) (601) (573) (716)
Proceeds from sale-leaseback transactions 101 5
Acquisitions, net of cash and restricted cash acquired (120) (18) (9,380) (7,094) (8) (6) (118) (7) (11) (27) (24) (84) (38) (60) (155) (613) (83) (111) (126) (124)
Proceeds from sale of subsidiaries, net of cash and restricted cash sold 679 15 (1,943) 6 834
Other 25 11 1 31 11 20 85 (31) 27 23 72 (5) (1) 1 5 26 2 4 10
Net cash used in investing activities (1,242) (771) (10,362) (8,514) (119) (805) (2,130) (1,993) (1,440) (847) (1,107) (1,867) (1,234) (1,370) (1,333) (1,597) (709) (829) (910) (891)
Commercial paper borrowings (repayments), net 200 (1,000) 1,000
Proceeds from issuance of short-term loan 5,000
Repayment of short-term loan (5,000)
Net borrowings (repayments) of short-term debt (252) 252 (255) 255 (1,070) 625 (2,560) 2,285
Proceeds from issuance of long-term debt 4,947 5,951 987 2,039 3,973 3,946 278 3,458
Repayments of long-term debt (432) (947) (1,425) (362) (16) (2,666) (1,515) (14) (2,431) (2,400) (2,374) (3,049) (5,138) (9,477) (8) (1,008) 14 (6,451) (1,017) (882)
Derivative settlements (7) (25)
Repurchase of common stock 1 3 2 (2,018) (1,500) (2,000)
Dividends paid (779) (779) (795) (779) (719) (726) (740) (722) (660) (659) (650) (656) (644) (665) (663) (652) (651) (646) (657) (649)
Proceeds from exercise of stock options 35 122 24 96 41 162 51 297 109 110 118 212 15 83 12 154 27 72 10 101
Payments for taxes related to net share settlement of equity awards (6) (7) (134) (34) (33) (8) (267) (62) (7) (2) (156) (3) (13) (7) (52) (16) (27) (5) (36) (44)
Other 9 (89) 7 (128) 40 20 10 (149) 158 (3) 6 (17) (12) (4) (11) 4 2 5
Net cash provided by (used in) financing activities (972) (2,697) 3,626 2,726 (2,187) (3,218) (2,461) (2,650) (2,831) (1,967) (3,314) (3,244) (3,735) (6,117) (978) 2,675 (1,440) (2,968) (4,258) 816
Net increase (decrease) in cash, cash equivalents and restricted cash (4,850) (752) (828) 1,650 (4,258) 5,100 852 (1,080) (266) 2,707 1,426 (2,219) (1,402) (5,613) 4,808 4,383 485 (869) 170 1,873

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. CVS Health Corp. net cash provided by operating activities decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. CVS Health Corp. net cash used in investing activities increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. CVS Health Corp. net cash provided by (used in) financing activities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.